Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort-Reference-Cited by-同舟云学术

Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort

Published:2009-06-01 Issue:11 Volume:115 Page:2400-2409
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Giltnane Jennifer M.,Moeder Christopher B.,Camp Robert L.,Rimm David L.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24277/fullpdf

Reference26 articles.

1. Cell signaling by receptor tyrosine kinases;Schlessinger;Cell.,2000

2. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer;Osborne;Clin Cancer Res.,2005

3. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma;Abd El-Rehim;Br J Cancer,2004

4. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry;Esteva;Pathol Oncol Res,2001

5. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors;Hudelist;Breast Cancer Res Treat.,2003

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development;Molecular Aspects of Medicine;2024-02

2. MRTF promotes breast cancer cell motility through SRF-dependent upregulation ofDIAPH3expression;2023-12-22

3. Advances in PET/CT Imaging for Breast Cancer;Journal of Clinical Medicine;2023-07-07

4. A ROS/Akt/NF-κB Signaling Cascade Mediates Epidermal Growth Factor-Induced Epithelial-Mesenchymal Transition and Invasion in Human Breast Cancer Cells;World Journal of Oncology;2022-10

5. Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy;Vaccines;2022-09-17